Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR16337] to MBNL3
- Suitable for: WB, ICC/IF
- Reacts with: Human
Product nameAnti-MBNL3 antibody [EPR16337]
See all MBNL3 primary antibodies
DescriptionRabbit monoclonal [EPR16337] to MBNL3
Tested applicationsSuitable for: WB, ICC/IFmore details
Species reactivityReacts with: Human
Synthetic peptide within Human MBNL3 aa 250-350. The exact sequence is proprietary.
Database link: Q9NUK0
- WB; Human placenta lysate. ICC/IF: JAR cells.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferpH: 7.20
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab197590 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000. Detects a band of approximately 39 kDa (predicted molecular weight: 39 kDa).|
FunctionMediates pre-mRNA alternative splicing regulation. Acts either as activator or repressor of splicing on specific pre-mRNA targets. Inhibits cardiac troponin-T (TNNT2) pre-mRNA exon inclusion but induces insulin receptor (IR) pre-mRNA exon inclusion in muscle. Antagonizes the alternative splicing activity pattern of CELF proteins. May play a role in myotonic dystrophy pathophysiology (DM). Could inhibit terminal muscle differentiation, acting at approximately the time of myogenin induction.
Tissue specificityHighly expressed in the placenta.
Sequence similaritiesBelongs to the muscleblind family.
Contains 4 C3H1-type zinc fingers.
Cellular localizationNucleus. Cytoplasm. Greater concentration in the nucleus. In both DM1 and DM2 patients, colocalizes with nuclear foci of retained expanded-repeat transcripts.
- Information by UniProt
- A530038J18Rik antibody
- AI661274 antibody
- CHCR antibody
Anti-MBNL3 antibody [EPR16337] (ab197590) at 1/1000 dilution + Human placenta lysate at 10 µg
Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated at 1/1000 dilution
Predicted band size: 39 kDa
Observed band size: 39 kDa
Blocking/Dilution buffer: 5% NFDM/TBST.
The expression is consistent with what has been described in the literature (PMID:)11929853.
ab197590 staining MBNL3 in JAR (human choriocarcinoma) cells by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with 4% Paraformaldehyde and permeabilized with 0.1% Triton X-100. Samples were incubated with primary antibody at a dilution of 1/500. A goat anti rabbit IgG (Alexa Fluor® 488) (ab150077) was used as the secondary antibody at a dilution of 1/1000. DAPI was used as a nuclear counterstain.
Control: PBS only
ab197590 has not yet been referenced specifically in any publications.